To access this element change to forms mode OFF
Grant Award View - GA386203
Treating chemoresistant ovarian cancer: Blocking follistatin signalling...
GA ID:
GA386203
Agency:
Cancer Australia
Approval Date:
18-Jun-2024
Publish Date:
2-Jul-2024
Category:
Cancer
Grant Term:
18-Jun-2024 to 1-May-2026
Value (AUD):
$199,816.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 23/24 CA
Grant Program:
2023 Priority-driven Collaborative Cancer Research scheme
Grant Activity:
Treating chemoresistant ovarian cancer: Blocking follistatin signalling to enhance the effects of chemotherapy and prevent recurrence of chemoresistant disease
Purpose:
Ovarian cancer remains one of the deadliest cancers in terms of survival outcomes largely due to the development of drug resistance. The research team recently discovered a novel secreted protein, follistatin, promotes drug resistance in ovarian cancer cells and patients. This project aims to neutralise the follistatin signalling pathway by developing an anti-follistatin nanobody. Success of this research project has the potential to increase drug responsiveness and cure rates of ovarian cancer patients.
GO ID:
GO Title:
2023 Priority-driven Collaborative Cancer Research Scheme for funding commencing in 2024
InternalReferenceId:
2023/PCRS/0074_Cole
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
University of Sydney
Recipient ABN:
15 211 513 464
Grant Recipient Location
Suburb:
Camperdown
Town/City:
Sydney
Postcode:
2006
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW
Postcode:
2006
Country:
AUSTRALIA